Pulmonary embolism (PE) is a condition characterised by an obstruction of the pulmonary arterial system by one or more emboli. Advanced clinical practitioners are often faced with ruling out a diagnosis of PE in patients with non-specific symptoms such as dyspnoea and pleuritic chest pain, which can be fairly mild and therefore a diagnosis of PE easily missed. PEs can be a challenge to diagnose, especially in elderly people, since it can be difficult to differentiate their symptoms from other less serious illnesses. Widely used scoring tools are helpful to calculate a patient's probability of having a PE. The Wells score is the most widely used pre-test clinical probability indicator of PE used in the UK, which scores the patient's probability of having a PE based on their risk factors. The D-dimer test is a relatively simple investigation to rule out venous thromboembolism (VTE) but can be raised for various reasons other than PE. Computed tomography pulmonary angiography (CTPA) is regarded as the gold standard imaging modality for investigation of acute PE but ventilation-perfusion (VQ) scans can be used as an alternative imaging technique for diagnosing PE in those where CTPA is contraindicated. Thrombolysis is underused in clinical practice due to the fear of adverse bleeding events. Patients without a massive or sub-massive PE are treated with anticoagulant therapy, usually commencing with subcutaneous low-molecular-weight heparin and switching over to a direct oral anticoagulant (DOAC). There has been a shift away from treatment with warfarin for the prevention and treatment of VTE over the past decade.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.12968/bjon.2020.29.1.22 | DOI Listing |
Cardiovasc Hematol Disord Drug Targets
January 2025
Division of Pulmonary and Critical Care Medicine, Texas Tech University Health Sciences Center, El Paso, TX, USA.
Background: Pulmonary embolism (PE) is a frequent cause of death. Acute PE may be treated either with full anticoagulation (AC) alone or thrombolytic therapy with systemic tissue-- type-plasminogen-activator (tPA) based on risk assessment. Currently, AC is the standard of care for most patients with intermediate-high-risk PE, with low-dose tPA emerging as an effective alternative.
View Article and Find Full Text PDFJACC Case Rep
January 2025
Department of Adult Congenital Heart Disease, University of Virginia, Charlottesville, Virginia, USA.
A 44-year-old man with a history of tricuspid atresia and discontinuous pulmonary arteries with palliative correction from a Waterston procedure and a modified central shunt presented with back pain, fevers, dyspnea, and cough. Treatment for pneumonia was unsuccessful. On computed tomography angiography he was found to have a subacute pulmonary embolism, potentially iatrogenic.
View Article and Find Full Text PDFVasa
January 2025
Department of Vascular Surgery, Aristotle University of Thessaloniki, AHEPA University General Hospital, Thessaloniki, Greece.
We investigated the safety and efficacy of rivaroxaban as routine thromboprophylaxis after endovenous thermal ablation (EVTA). Adhering to the PRISMA 2020 guidelines, we conducted a systematic review for studies published up to April 2024. Primary endpoints included endovenous heat-induced thrombosis (EHIT) class ≥ II, deep vein thrombosis (DVT), major and minor bleeding and the composite endpoint of major thromboembolic complications including any incidents of EHIT ≥ III, DVT or pulmonary embolism (PE).
View Article and Find Full Text PDFMed Sci Monit
January 2025
Department of Emergency Medicine, Sakarya University Faculty of Medicine, Adapazari, Turkey.
BACKGROUND The leuko-glycemic index (LGI) combines the white blood cell count and blood glucose levels and is calculated by multiplying the 2 values and dividing them by 1000. This study aimed to compare the prognostic value of the LGI in 199 patients with acute pulmonary embolism (APE) with and without diabetes mellitus. MATERIAL AND METHODS This study was conducted retrospectively on 199 patients who were admitted to the Emergency Department of Sakarya Training and Research Hospital between January 1, 2019, and December 31, 2022, and received a diagnosis of APE by pulmonary angiography.
View Article and Find Full Text PDFJ Ethnopharmacol
January 2025
State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin, China.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!